Hemangiosarcoma
"Immunotherapy treatment". Riney Canine Health Center. Cornell University College of Veterinary. Retrieved 1 June 2023. Ward, H ...
Timeline of historic inventions
2011: HIV treatment as prevention (HPTN 052) 2012: Discovery of the Higgs boson 2013: Cancer immunotherapy 2014: The first ... Couzin-Franken, Jenifer (20 December 2013). "Cancer Immunotherapy". Science. 342 (6165): 1432-1433. doi:10.1126/science. ...
Levamisole
Dillman RO (February 2011). "Cancer immunotherapy". Cancer Biotherapy & Radiopharmaceuticals. 26 (1): 1-64. doi:10.1089/cbr. ...
Chemoimmunotherapy
As for immunotherapy, it early mentioned by James Allison, now at the University of Texas MD Anderson Cancer Center in Houston ... Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or ... "Cancer immunotherapy." (2013) Chen, Gang, and Leisha A. Emens. "Chemoimmunotherapy: reengineering tumor immunity." Cancer ... Immunology, Immunotherapy (2013).[2] Coiffier, Bertrand, et al. "CHOP chemotherapy plus rituximab compared with CHOP alone in ...
2010s
Couzin-Franken, Jenifer (20 December 2013). "Cancer Immunotherapy". Science. 342 (6165): 1432-1433. doi:10.1126/science. ... Cancer immunotherapy 2014: Rosetta comet mission 2015: CRISPR genome-editing method 2016: The Laser Interferometer ...
Breakthrough of the Year
Jenifer Couzin-Franken (20 December 2013). "Cancer Immunotherapy". Science. Retrieved 22 December 2013. Eric Hand (19 December ... Cancer immunotherapy 2014: Rosetta comet mission 2015: CRISPR genome-editing method 2016: First observation of gravitational ...
Melanoma
The therapy combination of dabrafenib and trametinib has a 3-year PFS of 23%, and 5-year PFS of 13%. Immunotherapy is aimed at ... June 2014). "Melanoma immunotherapy". Cancer Biology & Therapy. 15 (6): 665-74. doi:10.4161/cbt.28555. PMC 4049781. PMID ... Talimogene laherparepvec (T-VEC) (which is a herpes simplex virus type 1-derived oncolytic immunotherapy), was shown to be ... The five-year progression-free survival for immunotherapy with pembrolizumab is 21%. A therapeutic approach that includes the ...
Lymphocyte-activation gene 3
"Oncology Pipeline at Immutep , Immunotherapy Treatment". www.immutep.com. Retrieved 2019-12-09. Avice M; Sarfati M; Triebel F; ... Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various ...
National Fibromyalgia Association
Immunotherapy Weekly. November 17, 2004. Retrieved July 19, 2009. "NFA History". National Fibromyalgia Association. Archived ...
Dartmouth Cancer Center
... and immunotherapy. DCC has 25 separate programs for treating different cancers. These include: Blood & Marrow Transplantation ... Cancer Control Cancer Mechanisms Epidemiology and Chemoprevention Imaging and Radiobiology Immunology and Immunotherapy ...
Azoximer bromide
Immunotherapy 2018; 10:131 137. Karaulov AV, Bykov AS, Volkova NV. Review of grippol family vaccine studies and modern adjuvant ... Immunotherapy 2018; 10:131 137. Shulzhenko AE. Immunomodultor Polioksidoni - novoe napravlenie v leqenii HSV-2 infekcii pri ee ... Obosnovanie immunoterapii pri leqenii recidiviruwego genitalnogo hlamidioza [Rationale for immunotherapy of recurrent ...
Epitopoietic Research Corporation
Sitoiganap (EU)/Gliovac/ERC1671 is an immunotherapy vaccine that trains the body's immune system to attack a Glioblastoma ( ... "ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, ... "ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, ... along with tumor cells from three other donors.ERC1671 is an immunotherapy vaccine designed to train the body's immune system ...
Alberto Mantovani
2013). Cancer Immunotherapy. Macrophages: biology and role in the pathology of diseases. Springer. 2014. I guardiani della vita ...
Spontaneous remission
Hobohm, U.; Stanford, J. L.; Grange, J. M. (2008). "Pathogen-associated molecular pattern in cancer immunotherapy". Critical ... Immunotherapy. 50 (8): 391-6. doi:10.1007/s002620100216. PMID 11726133. S2CID 109998. Zahl, P. H.; Maehlen, J.; Welch, H. G. ( ... Immunotherapy. 62 (8): 1283-92. doi:10.1007/s00262-013-1455-1. PMID 23832140. S2CID 26031460. Rohdenburg, G. L. (1 April 1918 ...
Interleukin 25
Immunotherapy. 59 (6): 805-17. doi:10.1007/s00262-009-0802-8. PMID 20012860. S2CID 1895002. Yao X, Sun Y, Wang W, Sun Y (May ...
Immunosenescence
Immunotherapy. 65 (4): 417-426. doi:10.1007/s00262-015-1750-0. PMID 26288343. S2CID 32642259. Yang OO, Lin H, Dagarag M, Ng HL ... Immunotherapy. 65 (4): 453-463. doi:10.1007/s00262-015-1720-6. PMID 26059279. S2CID 20498123. Gibson KL, Wu YC, Barnett Y, ...
Cancer
A variety of therapies using immunotherapy, stimulating or helping the immune system to fight cancer, have come into use since ... Weiss JM (2020). "The promise and peril of targeting cell metabolism for cancer therapy". Cancer Immunology, Immunotherapy. 69 ... Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269-77. doi:10.1038/nm0303-269. ...
Kinetic-segregation model of T cell activation
Immunotherapy. 59 (8): 1197-209. doi:10.1007/s00262-010-0844-y. PMID 20309546. S2CID 10279696. James, SE; Greenberg, PD; Jensen ...
GcMAF
Yamamoto, N.; Suyama, H.; Nakazato, H.; Yamamoto, N.; Koga, Y. (2014). "Retraction Note to: Immunotherapy of metastatic ... Retracted) Yamamoto, Nobuto; Ushijima, Naofumi; Koga, Yoshihiko (January 2009). "Immunotherapy of HIV-infected patients with Gc ... Retracted) Yamamoto, Nobuto; Suyama, Hirofumi; Yamamoto, Nobuyuki; Ushijima, Naofumi (15 January 2008). "Immunotherapy of ... Immunotherapy. 63 (12): 1349. doi:10.1007/s00262-014-1616-x. PMID 25297451. "Retraction". International Journal of Cancer. 135 ...
Flap structure-specific endonuclease 1
Journal of Immunotherapy. 12 (4): 219-223. doi:10.1097/00002371-199211000-00001. PMID 1477073. Li X, Li J, Harrington J, Lieber ...
Interleukin 6
Immunotherapy. 55 (6): 684-698. doi:10.1007/s00262-005-0047-0. PMID 16094523. S2CID 11019678. Smith SE, Li J, Garbett K, ... "Mechanisms and applications of interleukins in cancer immunotherapy". International Journal of Molecular Sciences. 16 (1): 1691 ...
Polysaccharide-K
Fisher M, Yang LX (2002). "Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy". ... Immunotherapy. 56 (6): 905-11. doi:10.1007/s00262-006-0248-1. PMID 17106715. S2CID 161680. Mitomi T, Tsuchiya S, Iijima N, et ... Immunotherapy. 18 (3): 149-54. doi:10.1007/BF00205503. PMID 6391658. S2CID 24000083. Kobayashi H, Matsunaga K, Oguchi Y (1995 ...
Skin cancer in horses
Journal of Immunotherapy. 34 (1): 58-64. doi:10.1097/cji.0b013e3181fe1997. PMID 21150713. S2CID 23807735. Taintor, J; S. ...
Brain metastasis
Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M (May 2018). "Cancer immunotherapy in patients with brain ... Immunotherapy, for instance Anti-PD-1 alone or in combination with anti-CTLA-4, appears to be effective in some patients with ... metastases". Cancer Immunology, Immunotherapy. 67 (5): 703-711. doi:10.1007/s00262-018-2146-8. hdl:11573/1298742. PMID 29520474 ...
CyTOF
Immunotherapy. 62 (5): 955-65. doi:10.1007/s00262-013-1416-8. PMID 23564178. S2CID 8607382. Bjornson ZB, Nolan GP, Fantl WJ ( ...
Indoleamine 2,3-dioxygenase 2
Immunotherapy. 58 (1): 153-7. doi:10.1007/s00262-008-0513-6. PMID 18418598. S2CID 6199515. Ball HJ, Sanchez-Perez A, Weiser S, ...
Murine respirovirus
Tai JA, Chang CY, Nishikawa T, Kaneda Y (August 2019). "Cancer immunotherapy using the Fusion gene of Sendai virus". Cancer ... Ueda Y, Hasegawa M, Yonemitsu Y (2009). "Sendai Virus for Cancer Immunotherapy". Viral Applications of Green Fluorescent ... Harada Y, Yonemitsu Y (June 2011). "Dramatic improvement of DC-based immunotherapy against various malignancies". Frontiers in ... Immunotherapy. 57 (1): 73-84. doi:10.1007/s00262-007-0351-y. PMID 17602226. S2CID 8779015. Nishikawa T, Tung LY, Kaneda Y ( ...
PD-L1
In order to anticipate the effectiveness of gene therapy or systemic immunotherapy in blocking the PD-1 and PD-L1 checkpoints, ... Flies DB, Chen L (April 2007). "The new B7s: playing a pivotal role in tumor immunity". Journal of Immunotherapy. 30 (3): 251- ... PD-L1 analysis in TNBC is essential for selecting patients eligible for immunotherapy. Inter-observer and intra-observer ... Journal for Immunotherapy of Cancer. 8 (1): e000450. doi:10.1136/jitc-2019-000450. PMC 7247398. PMID 32439799. Kazan O, Kir G, ...
David G. Maloney
He is the medical director for cellular immunotherapy at Fred Hutch and the Bezos Family Immunotherapy Clinic at Seattle Cancer ... Turtle, C., Riddell, S. & Maloney, D. (2016). CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell ... Seminars in Oncology, 29 (1 supp 2), 2-9. Maloney, D. G. (2005). Immunotherapy for non-Hodgkin's lymphoma: monoclonal ... McGinley, Laurie (November 1, 2016). "Seattle center bets big on experimental immunotherapy". Washington Post. "Whitworth ...
CD4+ T cells and antitumor immunity
677-686 Qiu et al., 1999 G. Qiu, J. Goodchild, R.E. Humphreys and M. Xu, Cancer immunotherapy by antisense suppression of Ii ... Knutson, K. L.; Disis, M. L. (2005-08-01). "Tumor antigen-specific T helper cells in cancer immunity and immunotherapy". Cancer ... Immunology, Immunotherapy. 54 (8): 721-728. doi:10.1007/s00262-004-0653-2. ISSN 0340-7004. PMID 16010587. S2CID 7644008. Kim, ...